V体育ios版 - Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood
- PMID: 27677785
- PMCID: V体育平台登录 - PMC5358808
- DOI: 10.1111/xen.12262
V体育平台登录 - Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood
"V体育2025版" Abstract
Background: The complement system plays a crucial role in acute xenogeneic reactions after cardiac transplantation. We used an ex vivo perfusion model to investigate the effect of Cp40, a compstatin analog and potent inhibitor of complement at the level of C3. VSports手机版.
Methods: Fifteen wild-type pig hearts were explanted, cardiopleged, and reperfused ex vivo after 150 minutes of cold ischemia. Hearts were challenged in a biventricular working heart mode to evaluate cardiac perfusion and function. In the treatment group (n=5), the complement cascade was blocked at the level of C3 using Cp40, using diluted human blood. Untreated human and porcine blood was used for controls V体育安卓版. .
Results: Throughout the perfusion, C3 activation was inhibited when Cp40 was used (mean of all time points: 1. 11 ± 0. 34% vs 3. 12 ± 0. 48% control activation; P<. 01). Compared to xenoperfused controls, the cardiac index improved significantly in the treated group (6. 5 ± 4 V体育ios版. 2 vs 3. 5 ± 4. 8 mL/min/g; P=. 03, 180 minutes perfusion), while the concentration of lactate dehydrogenase as a maker for cell degradation was reduced in the perfusate (583 ± 187 U/mL vs 2108 ± 1145 U/mL, P=. 02). Histological examination revealed less hemorrhage and edema, and immunohistochemistry confirmed less complement fragment deposition than in untreated xenoperfused controls. .
Conclusions: Cp40 efficiently prevents C3 activation of the complement system, resulting in reduced cell damage and preserved function in wild-type porcine hearts xenoperfused ex vivo VSports最新版本. We suggest that this compstatin analog, which blocks all main pathways of complement activation, could be a beneficial perioperative treatment in preclinical and in future clinical xenotransplantation. .
Keywords: complement; compstatin; ex vivo; heart; xenotransplantation. V体育平台登录.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. VSports注册入口.
Conflict of interest statement (V体育平台登录)
J. D. L V体育官网入口. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for clinical applications.
Figures
References
-
- COWAN PJ, D’APICE AJ. Complement activation and coagulation in xenotransplantation. Immunol Cell Biol. 2009;87:203–208. - PubMed
-
- EKSER B, EZZELARAB M, HARA H, et al. Clinical xenotransplantation: the next medical revolution? Lancet. 2012;379:672–683. - "VSports" PubMed
-
- SAHU A, KAY BK, LAMBRIS JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996;157:884–891. - PubMed
Publication types
- "VSports在线直播" Actions
MeSH terms (VSports最新版本)
- "V体育2025版" Actions
- "VSports" Actions
- VSports最新版本 - Actions
- "VSports app下载" Actions
- VSports app下载 - Actions
- V体育2025版 - Actions
Substances
- "VSports最新版本" Actions
Grants and funding
LinkOut - more resources
Full Text Sources (VSports注册入口)
V体育2025版 - Other Literature Sources
Medical
Miscellaneous
